Radiotherapy for Salvage – Principles and ILROG Guidelines
Louis S. Constine
09:00–09:15
Radiotherapy techniques for salvage and re-irradiation
Bouthaina Dabaja
09:15–09:30
Long-term considerations in salvage therapy
Lena Specht
09:30–09:45
Radiation- and immunotherapy for relapsed or refractory HL
Christian Baues
09:45–10:00
Future of RT in Salvage – new approaches, alternatives to High Dose Chemotherapy
Joachim Yahalom
10:00–10:15
Panel Discussion
Simone Marnitz-Schulze
Joachim Yahalom
08:45 – 10:15
Room: Kleiner Saal
WorkshopMolecular Pathogenesis
Martin-Leo Hansmann
Christian Steidl
08:45–09:05
Somatic gene mutations in NLPHL and THRLBCL
Sylvia Hartmann
Bianca Schuhmacher
09:05–09:25
Microenvironment biology and outcome prediction in pediatric Hodgkin Lymphoma
Anja Mottok
Abstract Talk
CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma
Andrea Visentin
Abstract Talk
Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma
Wolfram Klapper
Abstract Talk
ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma
George Rassidakis
08:45 – 10:15
Room: Marsilius Saal
WorkshopDeveloping Health Care Environments
Anton Hagenbeek
Oliver Henke
08:45–09:05
Challenges at a Developing Cancer Center in East Africa
Oliver Henke
09:05–09:25
Takeda Access to Medicine Program in Subsaharan Africa
Judith Kinley
09:25–09:45
Hodgkin Lymphoma Care in Current Venezuela
Maria Alejandra Torres Viera
09:45–10:15
Panel Discussion
Anton Hagenbeek
Oliver Henke
08:45 – 10:15
Room: Großer Saal
WorkshopPET
Markus Dietlein
Michel Meignan
08:45–09:15
PET / CT – The perspective from the German Hodgkin Study Group
Carsten Kobe
09:15–09:45
PET guided strategy in Hodgkin lymphoma: issues and perspectives
Andrea Gallamini
09:45–10:15
Measurement of metabolic volume and threshold in Hodgkin Lymphoma: how to move to a standard
Olivier Casasnovas
10:30 – 12:00
Room: Kleiner Saal
WorkshopSurvivorship
Ananda Plate
Flora van Leeuwen
10:30–10:45
Genetic determinants of radiation-induced breast cancer after HL
Flora van Leeuwen
10:45–11:00
Genetic polymorphisms associated with anthracycline-induced cardiotoxicity
Leszek Wojnowski
11:00–11:15
Genetic determinants for acute radiation toxicity
Catharine West
11:15–11:30
Genetic susceptibility for treatment-related adverse effects: How can we make signi cant progress?
Lindsay Morton
11:30–12:00
Panel Discussion
10:30 – 12:00
Room: Großer Saal
WorkshopImmunotherapy: Chances & Pitfalls
Philippe Armand
Tim Illidge
10:30–11:00
The role of radiotherapy for Hodgkin Lymphoma in the era of PD-1 blockade
Tim Illidge
11:00–11:30
Impact of PD-1 blockade on the treatment landscape of Hodgkin Lymphoma
Philippe Armand
11:30–12:00
Pitfalls in clinical trial design and interpretation with immunotherapy
Stephen Ansell
10:30 – 12:00
Room: Marsilius Saal
WorkshopChallenges in older Lymphoma Patients
Pauline Brice
Jonathan Friedberg
10:30–10:45
The role of geriatric assessments in lymphoma
Alessandra Tucci
10:45–11:00
Chemotherapy combinations in elderly HL
Pauline Brice
11:00–11:15
German experience in elderly HL
Boris Böll
11:15–11:30
Brentuximab combinations in elderly HL, including checkpoint inhibitor
Jonathan Friedberg
11:30–11:45
Brentuximab / chemotherapy combinations in elderly HL
Andrew Evens
11:45–12:00
Panel Discussion
Pauline Brice
Jonathan Friedberg
10:30 – 12:00
Room: Martin & Augustin
(Dorint Hotel)
WorkshopMinimum Residual Disease
Anton Hagenbeek
Pier Luigi Zinzani
10:30–10:50
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in FL
Marie-Hélène Delfau-Larue
10:50–11:10
The role of ctDNA in research and decision making-Lessons from ctDNA in DLBCL
Mark Roschewski
11:10–11:30
The Hodgkin Lymphoma MRD consortium
Sven Borchmann
Michiel Pegtel
11:30–12:00
Panel discussion
Anton Hagenbeek
Pier Luigi Zinzani
12:15 – 13:45
Room: Großer Saal
Scientific Symposium
(by Sandoz Germany)
Biosimilar rituximab – a new treatment option
Andreas Engert
12:15–12:45
Biosimilar Development in Oncology
Theodor Dingermann
12:45–13:15
Clinical evidence for biosimilar rituximab
Bertram Glaß
13:15–13:45
Treatment of CD20 positive, lymphocyte-predominant Hodgkin lymphoma
Dennis Eichenauer
14:00 – 15:30
Room: Großer Saal
Scientific SessionImmunotherapy – Biomechanisms
Andreas Rosenwald
Margaret Shipp
14:00–14:20
T-cells and PD1 Inhibition in cHL
Margaret Shipp
14:20–14:40
Immune-Evasion
Maher K. Gandhi
Abstract Talk
Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma
Ingrid Glimelius
Abstract Talk
Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc
Naike Casagrande
Poster Pitch
Development of an α-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma
Cindy Schwartz
Abstract Talk
The peripheral blood Neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis
Annarosa Cuccaro
Abstract Talk
PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma
Kristiina Karihtala
16:00 – 17:30
Room: Großer Saal
Scientific Symposium
(by Takeda Oncology)
Advanced HL: How Can We Do Better?
Mark Hertzberg
16:00–16:10
Introduction: Brief overview of key milestones in HL management over recent years
Mark Hertzberg
16:10–16:30
Can we do better in front-line?
Astrid Pavlovsky
16:30–16:35
iPad Audience Q&A with panel discussion
16:35–16:55
Can we do better with salvage?
Craig H. Moskowitz
16:55–17:00
iPad Audience Q&A with panel discussion
17:00–17:20
Can we do better in assessing risk of failure throughout the patient journey?
Martin Hutchings
17:20–17:25
iPad Audience Q&A with panel discussion
17:25–17:30
Chairman’s wrap-up
Mark Hertzberg
17:45 – 19:15
Room: Großer Saal
Main ProgramOpening Ceremony
Introduction and Welcome from the Symposium Chairman
Andreas Engert
Welcoming Address
Volker Diehl
Welcoming Address
Stefan Herzig
Key Note Lecture: The role of patient advocacy and patient involvement in research